此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

子宫内膜癌前哨淋巴结活检 (ENDO-3)

2026年11月11日 更新者:Queensland Centre for Gynaecological Cancer

在明显的早期子宫内膜癌中比较前哨淋巴结活检与无腹膜后淋巴结清扫术的 III 期随机临床试验

Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with specific equipment & surgical dissection of the lymph node in which the dye first becomes visible. Despite this promising proposition & similar to a lymph node dissection, the value to patients, cost effectiveness & potential harms (e.g. lymphedema) of SNB compared to no-node dissection in EC has never been established. Aim: determine the value of SNB for patients, the healthcare system and exclude detriment to patients using a randomised approach 1:1. Stage 1 - 444 patients. Stage 2 additional 316 patients.

Primary Outcome Stage 1:

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

Primary Outcome Stage 2:

Treatment non-inferiority as evaluated by disease-free survival status at 4.5 years post-surgery, as measured by the time interval between the date of randomisation and date of first recurrence. Confirmation of recurrent disease will be ascertained through clinical assessment, radiological work-up and/or histological results.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Hypothesis: The primary hypothesis is that SNB will not cause detriment to patients (lymphoedema, morbidity, loss of quality of life) and not increase costs compared to patients without a retroperitoneal node dissection. The secondary hypothesis is that disease-free survival in patients without retroperitoneal node dissection is not inferior to those receiving SNB.

Aims: To determine the value of SNB for patients, the healthcare system and to exclude detriment to patients.

Objectives:

Primary Stage 1:

To determine the recovery of participants (defined as incidence of adverse events, lower limb lymphoedema and health-related QOL) and to the healthcare system (cost) of Sentinel Node Biopsy (SNB) for the surgical treatment of endometrial cancer.

Primary Stage 2:

Compare disease-free survival at 4.5 years for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection.

Secondary:

  • Compare patterns of recurrence and overall survival (OS) between the groups
  • Determine the cost-effectiveness of SNB
  • Compare Patient Reported Outcomes (PROMS) between the groups at 12 months from surgery
  • Compare Health Related Quality of Life (HRQL) and Fear of Recurrence between the groups at 12 months from surgery
  • Compare perioperative outcomes (duration of surgery, length of hospital stay, intraoperative blood loss, blood transfusion requirements) and the incidence of intra- and postoperative adverse events within 12 months from surgery between the groups
  • Compare lower limb lymphoedema at 12 months after surgery
  • Compare the need for postoperative (adjuvant) treatments between groups
  • Determine the impact of body composition and frailty on survival, quality of life, lymphoedema, peri-, intra- and postoperative outcomes
  • Compare follow-up strategies (clinical vs symptom checklist)
  • Translational Research - Trans-ENDO 3 - biobanking strategy - Compare the Molecular profile at 12 months from surgery between the groups

研究类型

介入性

注册 (估计的)

760

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Antioquia
      • Medellín、Antioquia、哥伦比亚、050025
        • 招聘中
        • Promotora Médica Las Américas S.A.
        • 接触:
        • 首席研究员:
          • Gabriel Rendon, MD
    • Bogotá, Distrito Capital
      • Bogotá、Bogotá, Distrito Capital、哥伦比亚、110131
        • 招聘中
        • Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo
        • 接触:
        • 接触:
        • 首席研究员:
          • David Viveros, MD
    • São Paulo
      • São José do Rio Preto、São Paulo、巴西、15090-000
      • São Paulo、São Paulo、巴西
      • São Paulo、São Paulo、巴西
        • 招聘中
        • Hospital Israelita Albert Einstein
        • 接触:
        • 接触:
          • Renato
        • 首席研究员:
          • Renato Moretti-Marques, MD
    • NUH Zone B
      • Singapore、NUH Zone B、新加坡、119074
        • 招聘中
        • National University Hospital and National University Cancer Institute
        • 接触:
        • 接触:
        • 首席研究员:
          • Joseph Ng Soon Yau, MD
        • 副研究员:
          • Pearl S Tong, MD
        • 副研究员:
          • Jeffrey Low, MD
        • 副研究员:
          • Jeslyn Wong, MD
    • New South Wales
      • Camperdown、New South Wales、澳大利亚、2050
      • Liverpool、New South Wales、澳大利亚、2170
    • Queensland
      • Auchenflower、Queensland、澳大利亚、4066
        • 招聘中
        • The Wesley Hospital
        • 接触:
        • 首席研究员:
          • Andrea Garrett, MD
        • 副研究员:
          • Rhett Morton, MD
        • 接触:
      • Brisbane、Queensland、澳大利亚、4120
      • Buderim、Queensland、澳大利亚、4556
      • Everton Park、Queensland、澳大利亚、4053
      • Herston、Queensland、澳大利亚、4029
        • 招聘中
        • Royal Brisbane and Women's Hospital
        • 接触:
        • 首席研究员:
          • Andrea Garrett, MD
        • 副研究员:
          • Andreas Obermair, MD
        • 副研究员:
          • Russell Land, MD
        • 副研究员:
          • Piksi Singh, MD
        • 副研究员:
          • Shaun McGrath, MD
        • 接触:
      • South Brisbane、Queensland、澳大利亚、4101
        • 招聘中
        • Mater Hospital
        • 接触:
        • 副研究员:
          • Nisha Jagasia, MD
        • 副研究员:
          • Nimithri Cabraal, MD
        • 副研究员:
          • Rhett Morton, MD
        • 首席研究员:
          • Naven Chetty, MD
        • 接触:
        • 副研究员:
          • Simon West, MD
      • Southport、Queensland、澳大利亚、4215
        • 尚未招聘
        • Gold Coast University Hospital
        • 接触:
        • 首席研究员:
          • Elizabeth Goulding, MD
        • 接触:
      • Spring Hill、Queensland、澳大利亚、4000
    • Victoria
      • Heidelberg、Victoria、澳大利亚、3084
      • Melbourne、Victoria、澳大利亚、3002
        • 招聘中
        • Epworth Freemasons
        • 接触:
        • 首席研究员:
          • Adam Pendlebury, MD
      • Parkville、Victoria、澳大利亚、3052
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Houston Methodist Hospital
        • 接触:
        • 接触:
        • 首席研究员:
          • Behrouz Zand, MD
        • 副研究员:
          • Tarrik Zaid, MD
        • 副研究员:
          • Aparna Kamat, MD
        • 副研究员:
          • Anju Suri, MD
        • 副研究员:
          • Pedro Ramirez, MD
    • Ciudad Autónoma de Buenos Aires (caba)
      • Buenos Aires、Ciudad Autónoma de Buenos Aires (caba)、阿根廷
      • Buenos Aires、Ciudad Autónoma de Buenos Aires (caba)、阿根廷
        • 招聘中
        • Hospital Britanico
        • 接触:
        • 首席研究员:
          • Julian Di Guilmi, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour);
  2. Clinically stage I disease (disease confined to body of uterus);
  3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2;
  4. Signed written informed consent;
  5. Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning)
  6. All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease
  7. Myometrial Invasion on MRI of not more than 50%. (Only if participant is <45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries).
  8. Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause.

Exclusion Criteria:

  1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging.
  2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (>1 cm) on medical imaging;
  3. Estimated life expectancy of less than 6 months;
  4. Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy;
  5. Patients who have previously received radiation treatment to the pelvis
  6. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
  7. Patient compliance and geographic proximity that do not allow adequate follow-up;
  8. Patients with allergy to Indocyanine Green (ICG)
  9. Patients who have had previous retroperitoneal surgery
  10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy)
  11. Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu
  12. Uterine perforation during endometrial tissue sampling

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:TH BSO with SNB

Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.

Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the "sentinel node". These one or two nodes are thought to be first involved with cancer spread.

有源比较器:TH BSO without retroperitoneal node dissection

Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.

Removal of uterus, tubes and ovaries without retroperitoneal node dissection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Stage 1: Return to usual activities
大体时间:12 months from surgery

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

12 months from surgery
Stage 2: Disease Free Survival
大体时间:4.5 years from surgery

Compare disease-free survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection

4.5 years from surgery

次要结果测量

结果测量
措施说明
大体时间
Cost Effectiveness using QALYs using EuroQoL-5D (EQ-5D) Questionnaire
大体时间:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. We will also measure the quality-adjusted life years (QALYs) gained with the intervention and use this to undertake a cost-utility analysis. The QALY calculations will be based on health status measures for trial participants, with valuations of changes in health status and quality of life based on the EQ-5D

12 months from surgery
Cost Effectiveness measuring Intervention costs
大体时间:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Cost Effectiveness measuring GP and specialist consultations
大体时间:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness measuring radiology and imaging requirements
大体时间:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Cost Effectiveness measuring prescriptions and over the counter medicine requirements
大体时间:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness measuring community and health service requirements and days off work and informal care required by family and friends using a combination of the Health Services Questionnaire and clinical files
大体时间:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness: direct costs using a bottom-up approach by recording the volume of resource use in both groups of the trial, and then applying a unit cost to each component
大体时间:12 months from surgery

Direct costs wukk be ibtained for smaples of participants, stratified by hospital, operation and outcome to assess the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Perioperative Outcomes: Adverse Events
大体时间:12 months from surgery

Compare perioperative outcomes and the incidence of intra- and postoperative adverse events within 12 months from surgery between groups using Common Terminology Criteria for Adverse Events (CTCAE version 5)

12 months from surgery
Perioperative Outcomes: Length of Surgery
大体时间:At time of surgery

Compare the length of surgery between the two groups. This will be recorded in hh:mm on the surgery form.

At time of surgery
Perioperative Outcomes: Blood Loss during Surgery
大体时间:At time of surgery

Compare the blood loss between the two groups during surgery. This will be recorded in ml.

At time of surgery
Perioperative Outcomes: Blood Transfusion Requirements during Surgery
大体时间:At time of surgery

Compare the blood transfusion requirements between the two groups. This will be recorded in units and recorded on the Surgery Form and the Concomitant Medication Form.

At time of surgery
Perioperative Outcomes: Length of Hospital Stay
大体时间:At time of discharge from hospital following surgery

Compare the length of hospital stay between the two groups. The duration will be measured in days. Date of surgery being day 0.

At time of discharge from hospital following surgery
Health Related Quality of Life and Fear of Recurrence
大体时间:12 months from surgery

Change in Quality of Life using Functional Assessment of Cancer General (FACT-EN), Fear of Recurrence and PROMS between baseline and 1 year after surgery

12 months from surgery
Incidence of Lymphedema
大体时间:12 months from surgery

Compare lower limb lymphedema between groups

12 months from surgery
Adjuvant Treatment Requirements
大体时间:12 months from surgery

Compare the need for postoperative (adjuvant) treatments between groups and evaluate the impact of SNB on clinical decisions regarding adjuvant treatment. Any chemotherapy or radiation therapy required will be recorded on specific chemotherapy or radiation forms. Chemotherapy will be recorded in mg received and number of doses required including start/end dates. Radiation treatment received will be recorded as total dose of Gy and how many fractions, including start and end dates.

12 months from surgery
Value of Molecular Biomarkers
大体时间:24 months from surgery

Translational Research - Compare Molecular profile from surgery between the groups that require adjuvant therapy for 24 months.

24 months from surgery
Value of Molecular Biomarkers
大体时间:12 months from surgery

Translational Research - Compare the Molecular profile of Germline DNA at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
大体时间:12 months from surgery

Translational Research - Compare the Molecular profile of Circulating Tumour DNA at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
大体时间:12 months from surgery

Translational Research - Compare the Molecular profile of Plasma at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
大体时间:12 months from surgery

Translational Research - Compare the Molecular profile of Serum at 12 months from surgery between the groups

12 months from surgery
Overall Survival
大体时间:4.5 years from surgery

Compare overall survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection

4.5 years from surgery
Patterns of Recurrence - date and localization of 1st recurrence
大体时间:4.5 years from surgery

Date and localization of 1st recurrence as confirmed histologically and/or radiologically - Compare these patterns of recurrences between the groups. These will also be adjudicated by an independent committee to ensure accuracy of documented recurrence

4.5 years from surgery
Impact of body composition (sarcopenia) on surgical complications, recovery and overall survival
大体时间:4.5 years from surgery

Body mass measures are practical & sensitive for predicting health risks & outcomes. Sarcopenia is defined as loss of skeletal muscle mass & strength. It's been found to be associated with procedure-related morbidity, survival in cancer patients and increased use of healthcare. The concurrent appearance of low muscle mass with high adiposity (sarcopenic obesity) is common in people with chronic diseases. The trial will determine the role sarcopenia has on participants pre-operatively (via CT images & Bioimpedance Spectroscopy (BIS - if available at site) & postoperatively using the BIS in regard to survival in gynaecological malignancies, if it is a predictive factor for treatment adverse events & participants tolerability of treatment & compare diagnostic methods to determine medical fitness for surgery. BIS sends non-detectable electrical currents, at a range of frequencies through the body allowing precise measurement & analysis of impedance to currents by extracellular fluid

4.5 years from surgery
Impact of frailty on surgical complications, recovery and overall survival
大体时间:4.5 years from surgery

It has been reported consistently that frailty has a significant impact on the occurrence of adverse postoperative outcomes. Therefore, measuring frailty is important to estimate risks, determine the best treatment options, and to aid diagnosis and care planning. Frailty will be measured prior to surgery suing the validated tool - Frailty Phenotype. This may determine the impact frailty has on survival, quality of life, lymphedema, peri-, intra- and postoperative outcomes

4.5 years from surgery
Follow-Up Strategies
大体时间:4.5 years from surgery

Current institutional & clinical guidelines suggest patients need to be seen at regular follow up visits. The risk of developing a recurrence is higher within the initial period after surgery & the majority of recurrences develop within those first 3 years. Participants will ideally be seen 3 monthly for the first 3 years & 6 monthly until 4.5 years. The objective of follow up is that local recurrences from endometrial cancer are potentially curable. It helps to diagnose local recurrences as early as possible so that they are amenable for curative or effective palliative management. We will compare these clinical findings to a symptom checklist that will be completed by participants every 3 months from surgery until 4.5 years. This records patient reported symptoms that may indicate a recurrence. Comparing these findings should determine effective follow up strategies for this group of patients.

4.5 years from surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 学习椅:Andreas Obermair, Prof、Director, Queensland Centre for Gynaecological Cancer Research

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年1月18日

初级完成 (估计的)

2031年1月1日

研究完成 (估计的)

2031年2月1日

研究注册日期

首次提交

2019年8月26日

首先提交符合 QC 标准的

2019年8月27日

首次发布 (实际的)

2019年8月29日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • ENDO-3

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.